Cromos Pharma, an international full-service CRO has begun a risk-sharing platform partnering with biotech, pharma and device companies that have promising drug, biologics or medical device technologies. Cromos Pharma offers several business partnership algorithms through its risk-sharing model, including clinical research program conduct in exchange for equity or licensing opportunities.
"I have been intimately involved in the formation of a biotechnology company and understand how difficult it is to raise sufficient funds even for the most exciting and ground-breaking medical discoveries," said Dr Vlad Bogin, Cromos Pharma’s, CEO. " Cromos Pharma has experienced steady and sustained growth and is now positioned to offer companies with promising clinical programs mutually beneficial partnership algorithms."
"Over the years we have been approached by a number of biotech companies with compelling technologies," said Dr Andrey Tarakanov, company's managing director. " Cromos Pharma’s team would be asked to develop a trial protocol or perform a feasibility study, but then the process would stall due to company's financial constraints."
"We want to change this paradigm and help the companies advance the science we believe in," continued Bogin. "Cromos Pharma’s team is expert in clinical research, biopharmacology and medicine – this expertise and our facilities position Cromos Pharma to accurately evaluate medical technologies and select the best partners. We invite interested pharmaceutical, biotech, and medical device companies to reach out to us for an in depth evaluation of potential strategic partnerships."
